While the COVID-19 vaccines introduced many people to RNA-based medicines, RNA oligonucleotides have already been on the market for years to treat diseases like Duchenne Muscular Dystrophy and ...
A new paper published in Nature Biotechnology this week titled, “Template-independent enzymatic synthesis of RNA oligonucleotides,” provides details of a method for synthesizing single-stranded RNA ...
RNA-based medicines are transforming the way we treat disease—offering targeted, precision therapies for conditions ranging from rare genetic disorders to widespread chronic illnesses like diabetes, ...
The recognition of mRNA molecules as a transformative class of therapeutic drugs has soared, particularly with the development of COVID 19 mRNA vaccines. The cancer treatment landscape is similarly ...
A cell-free genomics approach silences cellular noise and reveals transcription drivers, improving our understanding of a ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A spinout from George Church’s ...
Elegen and Nutcracker Therapeutics launched a pilot program to demonstrate what they label the industry’s first fully synthetic, cell-free manufacturing platform for RNA-based personalized cancer ...
Caught in action: A research team has revealed how the molecular copying machine of the influenza virus, termed FluPol, interacts with the human copying machinery inside the infected cell to steal the ...
Elegen, a global leader in next-generation DNA manufacturing, and Nutcracker Therapeutics, a global leader in next-generation RNA design and manufacturing, today announced the launch of a pilot ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results